Skip to main content
OpenTrials
Completed

NCT Number: NCT06158347

Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients with Localized Breast Cancer

This study aimed to evaluate reducing the incidence of radiation dermatitis by assigning hyperbaric oxygen therapy to patients with localized breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Dermatitis Neoplasms Neoplasms by Site Radiation Dermatitis Radiation Injuries Radiodermatitis Skin Diseases Skin and Connective Tissue Diseases Wounds and Injuries

Age range

19 year–69 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Lee Jee Young

Goyang-si, Gyeonggi-do, 10414, South Korea

About this study

To evaluate the efficacy of hyperbaric oxygen therapy (HBOT) on the prevention of radiation dermatitis, patients with localized breast cancer between the ages of 19 and 69 were randomly assigned to HBOT group and usual care group in a 1:1 ratio during the period of adjuvant radiotherapy.

The primary purpose of this study was to administer oxygen therapy three times a week during the radiotherapy period for those who were recommended to receive radiotherapy with a Biological equivalent dose (BED10) of 60 Gy or more as adjuvant radiotherapy after breast-conserving surgery to determine the radiation at the end of radiotherapy. The purpose is to compare the incidence of radiation dermatitis of therapy oncology group grade (RTOG grade) grade 2 or higher between the two groups.

The secondary purpose of this study is to evaluate/compare the following items in the relevant treatment group.

  • Comparison of the incidence of radiation dermatitis according to RTOG grade
  • Catterall skin scoring profile score comparison
  • Comparison of Skindex-29 questionnaire scores
  • Numeric rating scale score comparison
  • Investigation of radiation therapy dose, frequency, schedule, and medical history
  • Health-related quality of life questionnaire (EORTC-QLQ-C30)
  • Health-related quality of life measurement tool (EQ-5D)
  • Safety evaluation
  • Health-related quality of life measurement tool (EQ-5D)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between the ages of 19 and 69
  • Patients with biopsy confirmed invasive breast cancer
  • Patients who have undergone breast-conserving surgery for the purpose of tumor resection and require adjuvant radiotherapy or have undergone adjuvant radiotherapy within 5 times.
  • The Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Those who understand the content of the study, agree to participate in the study, and provide written informed consent

Exclusion criteria

  • Subjects with distant metastases of cancer
  • Those whose cancer has invaded the skin of the breast (T4) or who have unhealed wounds on the skin
  • Patients who have a history of radiotherapy of the cervical thoracic region for other reasons in the past
  • Patients with a history of connective tissue disease
  • Subjects with uncontrolled diabetes with HbA1c 7.0 or higher
  • Pneumothorax and symptomatic upper respiratory tract infection
  • If it is judged that there will be a significant decrease in respiratory function
  • Undergoing treatments known to interact with hyperbaric oxygen therapy, such as cisplatin, doxorubicin, bleomycin, disulfiram, etc.
  • When it is judged that diseases other than cancer (dementia, cerebrovascular disease, severe renal failure, etc.) may have a significant effect on the decline of physical function.
  • If it is determined that the life expectancy is not sufficient follow-up within 3 months.
  • Pregnant and lactating women
  • Other persons who are judged by the researcher to be unsuitable for research

Treatment and study plan

hyperbaric oxygen chamber

Device

Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).

Primary outcomes

  1. incidence of grade 2 or more dermatitis according to RTOG toxicity scale

    Time frame: At the end of 6 weeks

    ① Grade 0: No change before or after treatment (No change over baseline)

    • Grade 1: Cystic lesions, erythema with faint or reduced skin luster, implantation, dry epidermis shedding, and decreased sweating.

    (Follicular, faint or dull erythema, epilation, dry desquamation, decreased sweating)

    • Grade 2: Tender or bright erythema, ecchymosis, desquamation of the wet epidermis, and moderate edema.

    (Tender or bright erythema, patchy moist desquamation, moderate edema)

    • Grade 3: Confluent skin lesions, desquamation of the wet epidermis other than the area where the skin is folded, pitting edema (Confluent, moist desquamation other than skin folds, pitting edema)
    • Grade 4: Ulcerative bleeding, skin necrosis (Ulceration hemorrhage, necrosis)

Secondary outcomes

  1. RTOG toxicity

    Time frame: At the end of Day 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

    ① Grade 0: No change before or after treatment (No change over baseline)

    • Grade 1: Cystic lesions, erythema with faint or reduced skin luster, implantation, dry epidermis shedding, and decreased sweating.

    (Follicular, faint or dull erythema, epilation, dry desquamation, decreased sweating)

    • Grade 2: Tender or bright erythema, ecchymosis, desquamation of the wet epidermis, and moderate edema.

    (Tender or bright erythema, patchy moist desquamation, moderate edema)

    • Grade 3: Confluent skin lesions, desquamation of the wet epidermis other than the area where the skin is folded, pitting edema (Confluent, moist desquamation other than skin folds, pitting edema)
    • Grade 4: Ulcerative bleeding, skin necrosis (Ulceration hemorrhage, necrosis)

  2. CSSP

    Time frame: At the end of Day 1, week 5, week 8, week 9, week 10

    CSSP is a numerical scale-type evaluation tool developed by Fowler in 1965 to evaluate skin reactions in rats and modified by Catterall for application to patients with radiotherapy-induced dermatitis. [14] Graded from 1 to 10 points depending on the symptoms and severity of dermatitis

  3. skindex-29

    Time frame: At the end of Day 1, week 5, week 8, week 9, week 10

    Skindex-29 is a revision of the existing 61-item Skindex to 29 questions for patients with skin diseases. It maintains the excellent reproducibility, reliability, construct validity, and content validity of the Skindex, while improving the patient's quality of life through symptoms, function, and quality of life. It is a quality of life assessment tool designed to evaluate emotions on three scales. It consists of three scales: function (Fx), emotion (em), symptom (symptom) and a total score (total), linearly ranging from 0 (not affected) to 100 (always affected). A total of 29 items are scored for each scale, and then averaged to calculate the overall quality of life. The lower the score of Skindex-29, the better the quality of life.

  4. NRS

    Time frame: At the end of Day 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

    NRS is one of the evaluation tools that quantifies the level of discomfort. NRS 0 is defined as no discomfort, and NRS 10 is defined as the maximum discomfort the patient can think of.

  5. EORTC

    Time frame: At the end of Day 1, week 5, week 8, week 9, week 10

    This is a questionnaire developed with 30 questions to measure the general quality of life of tumor patients. It evaluates overall quality of life and emotional health by dividing it into five areas: physical, role, cognitive, emotional, and social.

  6. EQ-5D

    Time frame: At the end of Day 1, week 5, week 8, week 9, week 10

    It is the most widely used method of indirect measurement among various indirect measurement methods as it evaluates health status from multiple aspects, and then indirectly calculates the weight of the quality of a specific health status using a preference score assigned in advance for each functional level. The EQ-5D-5L consists of five questions, each of which asks about mobility, self-care, usual activities, pain, and anxiety/depression.

  7. Drug Consumption

    Time frame: At the end of Day 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

    The type, dose, route of administration, frequency, and purpose of medications administered or taken during the study period (medications prescribed due to current medical history or rescue drugs) will be recorded.

  8. Adverse events

    Time frame: At the end of Day 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

    To compare the occurrence of adverse events between the two groups and verify their safety. An adverse event is an undesirable or unintended sign, symptom, or disease that occurs after a procedure in a clinical study and does not necessarily have a causal relationship with the procedure. The investigator will analyze the incidence of adverse events, laboratory abnormalities, and serious adverse events that are suspected to be associated with treatment.

Sponsors and collaborators

Lead sponsor

Ilsan Cha hospital

Other

Registry information

Official study title

Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients with Localized Breast Cancer : a Randomized Controlled, Pilot Study

Acronym: HBOT

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 6, 2023
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.